Personalised medicine not yet validated for cancer

In theory, the prescription of medication compensating the deregulation of molecular pathways should lead to better treatment of cancer. However, in a multicentre phase II study in France, this approach did not render longer periods of progression-free survival. The results, published in The Lancet, raise concerns about the implementation of personalised medicine in cancer. Continue reading